Purchase Short-Term Access

Review: Varenicline for tobacco cessation does not increase CV serious adverse events

Paul Krebs, PhD; Scott E. Sherman, MD, MPH

Annals of Internal Medicine 2012;157:JC2-2. doi:10.7326/0003-4819-157-4-201208210-02002

Purchase Online access to this article for 24 hours

Annals of Internal Medicine

Forgot Your Password?

to gain full access to the content and tools.

Learn more about subscription options

Forgot your password?

Enter your username and email address. We'll send you a reminder to the email address on record.

Username* (Required)

Email Address* (Required)